Creative Biolabs Offers Different Types of Virus-Like Particles (VLPs) Based Vaccines

April 23 18:36 2019

New York, April 23, 2019 Creative Biolabs, a professional vaccine company, now offers Virus-Like Particles (VLPs) Based Vaccine that can generate effective and long-lasting protection.

Virus-like particles refer to compounds consisting of one or more structural proteins that, have the ability to self-assemble when expressed recombinantly, which can resemble and mimic the structure of real viruses without being infectious, and have significant potential to trigger a strong immune response without causing any actual harm.  Compared with individual proteins or peptides, virus-like particles exhibit more similar conformational epitopes to the native viruses, significantly improving antibody reactivity or immune system response.

Most importantly, owing to their non-duplicate characteristic, virus-like particles provide a safer choice for attenuated viruses. VLP vaccine production can start immediately (12 weeks) after the strain is sequenced while a traditional vaccine usually needs 9 months. Based on years of experience in vaccine development, Creative Biolabs can serve clients a complete virus-like particles vaccine system covering vaccine design and production, including but not limited to:

  • Different types of VLPs for vaccine development: VLPs of structurally simple viruses (such as hepatitis E virus, HPV, norwalk virus, canine and porcine parvovirus VLPs); VLPs with lipid envelope (such as HIV, RSV, HBsAg, herpes simplex, NDV, HCV, Ebola, RVFV, Hantaan and Marburg virus VLPs); VLPs with multiple protein layers (such as IBDV, poliovirus, bluetongue virus, enterovirus 71 and rotavirus VLPs);
  • A range of VLP production systems covering bacterial, yeast, insect mammalian cells and more;
  • Different culture modes for VLP production: batch, fed-batch, continuous or perfusion mode;
  • Downstream processing of VLPs;
  • Quality monitor & control.

Meanwhile, Creative Biolabs also provides the development of chimeric VLP based vaccines that pave the way for the development of vaccine candidates with a broader, more powerful and comprehensive protection against diseases. More information on vaccines can be reached at https://www.creative-biolabs.com/vaccine.

About

Creative Biolabs, headquartered in New York, is a leading custom service provider in the field of vaccine development, preclinical assessment and GMP manufacturing. The technical and regulatory experts can provide vaccine developers with a full range of products and vaccine related services. Traditional and the most updated genetic engineering technologies are combined to efficiently produce highly immunogenic and safe vaccines to address emergency unmet medical needs. The service portfolio includes a full range of vaccine design for client’s specific requirements that covers vaccine target validation, vaccines targeting bacterial, viral, fungal, parasites, cancer markers and more. Formulation optimization services are also available for maximum potency, including improving delivery systems, a great variety of adjuvant products and services like PRR Ligands scanning and adjuvants synthesis.

 

Media Contact
Company Name: Creative Biolabs
Contact Person: Candy Swift
Email: Send Email
Phone: 1-631-619-7922
Address:45-1 Ramsey Road
City: Shirley
State: New York
Country: United States
Website: https://www.creative-biolabs.com/vaccine